A Cross-sectional Study Describing the Current Status of Diagnosis and Treatment of Uroepithelial Cancer in Hospitals of Different Grades in Henan Province

A cross-sectional study describing the current status of diagnosis and treatment of uroepithelial cancer in hospitals of different grades in Henan Province

开始日期2024-10-30

申办/合作机构

The First Affiliated Hospital of Xinxiang Medical College

NCT06641934 / Not yet recruitingN/AIIT

Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients

开始日期2024-10-20

申办/合作机构

The First Affiliated Hospital of Xinxiang Medical College

NCT06409481 / Not yet recruitingN/AIIT

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

The aim of this observational study is to explore and analyze reports of cardiac or vascular adverse events linked to the administration of antineoplastic agents among patients diagnosed with tumors represented by advanced non-small cell lung cancer. The study leverages pharmacovigilance databases such as the World Health Organization (WHO) database (VigiBase), FDA Adverse Event Reporting System (FAERS), and others to gather individual safety case reports for analysis.

开始日期2024-06-01

申办/合作机构

The First Affiliated Hospital of Xinxiang Medical College

100 项与 The First Affiliated Hospital of Xinxiang Medical College 相关的临床结果

登录后查看更多信息

0 项与 The First Affiliated Hospital of Xinxiang Medical College 相关的专利（医药）

登录后查看更多信息

282

项与 The First Affiliated Hospital of Xinxiang Medical College 相关的文献（医药）

2024-02-25·Zhen ci yan jiu = Acupuncture research

电针督脉对脊髓损伤大鼠脊髓组织线粒体融合及神经干细胞增殖分化的影响.

Article

作者: Su, Kai-Qi ; Gao, Jing ; Chang, Wen-Tao ; Feng, Xiao-Dong ; Wu, Ming-Li ; Duan, Zhao-Yuan

目的: 观察电针督脉对脊髓损伤（SCI）大鼠损伤区脊髓组织中线粒体融合及神经干细胞增殖分化的影响，探讨电针促进SCI神经修复的机制。方法: SD大鼠随机分为假手术组、模型组和电针组，每组各15只。采用精密打击器打击法构建胸10节段SCI模型。电针组大鼠予以电针“大椎”“脊中”，30 min/次，1次/d，共14 d。用Basso-Beattie-Bresnahan （BBB）运动功能评分法评估大鼠后肢的运动功能；HE染色法、尼氏染色法观察大鼠损伤区脊髓组织病理变化及神经元数量；免疫荧光染色法检测大鼠损伤区脊髓组织中神经干细胞增殖标记物巢蛋白（Nestin）、线粒体融合相关蛋白视神经萎缩蛋白1（OPA1）及神经干细胞转录因子性别决定区Y框蛋白2（SOX2）的阳性表达；实时荧光定量PCR法、Western blot法检测大鼠脊髓组织中Nestin mRNA及蛋白的表达。结果: 与同时点假手术组比较，模型组大鼠造模后BBB评分降低（P<0.001）；脊髓组织中神经元肿胀、破裂、坏死严重，尼氏小体溶解严重，神经元数量减少（P<0.001）；Nestin、OPA1、SOX2阳性表达及Nestin蛋白和mRNA相对表达量均升高（P<0.001，P<0.05，P<0.01）。与模型组比较，电针干预第7、14天时电针组大鼠BBB评分，Nestin、OPA1、SOX2阳性表达，以及Nestin蛋白和mRNA相对表达量均升高（P<0.05，P<0.01，P<0.001），脊髓神经元受损程度减轻，尼氏小体溶解程度减轻，神经元数量增加（P<0.05）。结论: 电针督脉可改善SCI大鼠运动功能，促进SCI区域神经元修复，其机制可能与电针督脉促进损伤区脊髓组织线粒体融合蛋白OPA1表达，增强神经干细胞增殖分化有关。.

2023-12-01·Renal failure

ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis

Article

作者: Wen, Yibo ; Yang, Jinghua ; Zhang, Yanping ; Feng, Jinjin ; Si, Feng ; He, Xiangfei ; Wang, Junkui ; Wu, Junwei ; Pu, Qingsong ; Wen, Jian Guo

This study investigated the mechanism of action of ABT-263 in the treatment of neurogenic bladder fibrosis (NBF)and its protective effects against upper urinary tract damage (UUTD). Sixty 12-week-old Sprague-Dawley (SD) rats were randomly divided into sham, sham + ABT-263 (50 mg/kg), NBF, NBF + ABT-263 (25 mg/kg, oral gavage), and NBF + ABT-263 (50 mg/kg, oral gavage) groups. After cystometry, bladder and kidney tissue samples were collected for hematoxylin and eosin (HE), Masson, and Sirius red staining, and Western Blotting (WB) and qPCR detection. Primary rat bladder fibroblasts were isolated, extracted, and cultured. After co-stimulation with TGF-β1 (10 ng/mL) and ABT-263 (concentrations of 0, 0.1, 1, 10, and 100 µmol/L) for 24 h, cells were collected. Cell apoptosis was detected using CCK8, WB, immunofluorescence, and annexin/PI assays. Compared with the sham group, there was no significant difference in any physical parameters in the sham + ABT-263 (50 mg/kg) group. Compared with the NBF group, most of the markers involved in fibrosis were improved in the NBF + ABT-263 (25 mg/kg) and NBF + ABT-263 (50 mg/kg) groups, while the NBF + ABT-263 (50 mg/kg) group showed a significant improvement. When the concentration of ABT-263 was increased to 10 µmol/L, the apoptosis rate of primary bladder fibroblasts increased, and the expression of the anti-apoptotic protein BCL-xL began to decrease.ABT-263 plays an important role in relieving NBF and protecting against UUTD, which may be due to the promotion of myofibroblast apoptosis through the mitochondrial apoptosis pathway.

2023-08-30·Diseases of the Esophagus

482. SECOND-LINE OF CAMRELIZUMAB PLUS NIMOTUZUMAB IN ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A SINGLE-ARM, OPEN-LABEL, PHASE 2 TRIAL

作者: Cui, Donghai ; Wang, Junsheng ; Wang, Feng ; Meng, Xiangrui ; Yang, Xiuli ; Hong, Yonggui ; Xia, Jin ; Ji, Yinghua

AbstractBackgroundAnti-PD-1 antibody camrelizumab monotherapy is recommended for the treatment of advanced second-line ESCC. However, the long-term survival is limited, and new effective treatments are needed. Epidermal growth factor receptor (EGFR) is usually over-expressed in more than 50% of ESCC patients(pts), and is a potential target for the treatment of ESCC. Our study aimed to assess the efficacy and safety of combination with camrelizumab and nimotuzumab (EGFR inhibitor) as second-line treatment for advanced ESCC.MethodsThis ongoing phase II trial in four sites in China enrolled pts aged 18–75 with unresectable locally advanced, locally recurrent, or metastatic ESCC that progressed or were intolerant after first-line treatment, and ECOG PS score of 0–1. Pts received 200 mg intravenous camrelizumab (Q2W) plus 400 mg intravenous nimotuzumab (QW) in 4-week cycles until disease progression, unacceptable adverse events (AEs) or withdrawal of consent. The primary endpoint was investigator-assessed objective response rate (ORR), overall survival (OS). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS).ResultsFrom 2/2021 to 4/2023, 28 of the planned 42 pts with an average 63 years old had been enrolled, including 18 (64%) males and 21 (75%) patients with an ECOG PS score of 1. Nine pts had previously used anti-PD-1/PD-L1 antibody. Among the 21 evaluable pts, 8 pts achieved partial response (PR), 13 pts stable disease (SD), illustrating an ORR of 38.0% and a DCR of 100%. Median PFS was not reached. 82.1% pts experienced adverse event(AE), with 21.4% being grade ≥ 3. The most frequent AE were RCCEP (57.1%), neutrophil count decreased (17.8%), white blood cell decreased (14.2%).ConclusionsCamrelizumab plus nimotuzumab demonstrated encouraging clinical efficacy and acceptable safety as second-line treatment, and might be a favorable option for pts with advanced ESCC. The study enrollment is ongoing, and further survival and safety data will be reported in the future. Clinical trial information: NCT03766178.

100 项与 The First Affiliated Hospital of Xinxiang Medical College 相关的药物交易

登录后查看更多信息

100 项与 The First Affiliated Hospital of Xinxiang Medical College 相关的转化医学

登录后查看更多信息